






* Neuroimmunology Unit, Department of Neurosciences, Ophthalmology and Genetics, and
Centre of Excellence for Biomedical Research, University of Genoa, Italy;
Laboratory of Neuroimmunology, IRCCS, S. Lucia, Rome, Italy;
Molecular Biology Laboratory and
# Tumor Progression Section, National Cancer Research Institute, Genoa, Italy;
¶ II Division of Haematology, S. Martino Hospital, Genoa, Italy; and
** Department of Neuroscience, University of Rome "Tor Vergata," Italy
Correspondence: Antonio Uccelli, M.D., Department of Neurosciences, Ophthalmology and Genetics, University of Genoa, Via De Toni 5, 16132, Genoa, Italy. E-mail: auccelli{at}neurologia.unige.it
|
|
|---|
-producing T cells in the CSF compared with peripheral blood, mostly but not exclusively in the CD45RO+ CCR7- CD27- compartment. T helper 1 (Th1) clones, established from the CSF of individuals with IND and from a healthy subject, similarly migrated to CXCL10, CXCL12, and CCL5. CXCL10, CXCL12, and CCL19 were increased in the CSF of individuals with neuroinflammation. These findings suggest that CSF is enriched in Th1-polarized memory T cells capable of differentiating into effector cells upon antigen encounter. These cells are recruited into the CSF by inducible chemokines. Thus, CSF represents a transitional station for T cells trafficking to and from the NS.
Key Words: MS chemokines T lymphocytes neuroimmunology cell trafficking
|
|
|---|
|
|
|---|
|
View this table: [in a new window] |
Table 1. Demographic and Laboratory Features of MS Patients and Subjects with OIND
|
(IFN-
) and PE-conjugated interleukin IL-4 monoclonal antibodies (BD Biosciences).
Generation of T cell clones
T cell clones were established from the CSF of a healthy subject, one individual with viral meningitis (as representative of OIND), and two MS patients by single-cell sorting with the MoFlo® cytometer (Cytomation, Fort Collins, CO). Clones were maintained with repeated cycles of stimulation with phytohemagglutinin (PHA; 2 µg/ml; Sigma-Aldrich). A healthy subject was defined as an individual suffering from symptoms mimicking a neurological deficit, which was subsequently found to be unrelated to a neurological disease.
Migration assays
Chemotaxis assays were performed in quadruplicate in Boyden chambers (Neuro Probe, Cabin John, MD). Chemoattractants were placed in the lower chamber (27 µl/well) and T cell clones in the upper chamber (100,000 in 50 µl/well), both diluted in serum-free medium. These compartments were separated by a polycarbonate filter with a 5-µm pore size. The cells that migrated into the lower chamber were counted under a light microscope. Results were expressed as migration index (MI) representing the ratio for each clone between cells migrated to a given chemokine and the same cells migrated in serum-free condition The following chemokines were used as chemoattractants: CCL3 (macrophage-inflammatory protein-1
(MIP-1
); 200 µg/ml), CCL5 (Rantes IP-10; 400 µg/ml), CXCL10 (IP-10; 200 µg/ml), and CXCL12 (stromal cell-derived factor-1
(SDF-1
); 500 µg/ml); all purchased from Pepro-Tech EC Ltd., London, UK). For chemotaxis inhibition experiments, T cell clones responsive to CCL5 were incubated for 30 min at 4°C with antibodies against CCR1 (7 µg/ml), CCR3 (25 µg/ml), and CCR5 (7 µg/ml), the three known CCL5 receptors (all from R&D Systems). Anti-CCL5-, -CXCL12-, and -CXCL10-blocking antibodies (from R&D Systems) were also used at different concentrations (1, 3, 6, and 9 µg/ml) to block the bioactivity of each chemokine, incubating the responsive clone for 30 min at room temperature (RT).
ELISA
Levels of IFN-
and IL-4 were measured in triplicate on the supernatants of CSF T cell clones 48 h following PHA stimulation using an ELISA method (Quantikine, R&D Systems). Similarly, levels of CXCL10, CXCL12, CCL5, CCL19, and CCL21 were analyzed on CSF supernatants by commercial ELISA kits (Quantikine for CXCL10, CXCL12, and CCL21; DuoSet for CCL5 and CCL19; all from R&D Systems).
Statistical analysis
To calculate significant differences between CSF and PBMC and between two groups of patients, a two-tailed Mann-Whitney U-test was used. ELISA results were compared by a nonparametric ANOVA test (GraphPad Prism 3.0, GraphPad Software, San Diego, CA). Significance was assigned at P< 0.05.
|
|
|---|
|
View this table: [in a new window] |
Table 2. Expression of Markers Suggesting a Th1 Memory Phenotye on CD4+ and CD8+ T Cells from Peripheral Blood Mononuclear Cells (PBMC) and Cerebrospinal Fluid (CSF) of Subjects with Multiple Sclerosis (MS) and Other Inflammatory Neurological Diseases (OIND)
|
![]() View larger version (49K): [in a new window] |
Figure 1. Coexpression of CCR7 and CXCR3 (a), CCR7 and CCR5 (b), and CD27 and CCR5 (c) on CSF T cells. (d) Coexpression of CCR5 and CXCR3 gating on CCR7+ T cells.
|

by CSF T cells by intracellular staining. We detected an over twofold increase of the percentage of T cells producing IFN-
in the CSF compared with the peripheral blood. We subsequently determined whether CD4+ and CD8+ CD45RO+ cells, which have lost CD27 and CCR7, indicating their differentiation to effector cells, are present in the CSF during an inflammatory response. Only a small fraction of the lymphocytes in the CFS had the phenotype of effector cells in individuals with MS and in subjects with OIND (Table 3
). CD45RO+ CD27- and CD45RO+ CCR7- lymphocytes from the CSF of both groups were always slightly higher in the CD4 as compared with the CD8 subset; in any case, the median was never above 7.3% (Table 3)
. A higher percentage of cells with such phenotypes was detected in the peripheral blood of both groups. It is interesting to note that a modest increase of CD4+ CD45RO+ CD27- and CD4+ CD45RO+ CCR7- was observed in the peripheral blood of subjects with OIND as compared with MS individuals (Table 3)
. The increased number of CD45RO+ CCR7- effector cells in the peripheral blood resided exclusively in two individuals with on-going, systemic, bacterial infections (neuroborreliosis) with subsequent involvement of the NS, where a direct role for systemic effector CD4+T cells has been established [13
]. IFN-
produced within the CSF was mostly detected into CCR7- CSF T cells, confirming their effector nature (Fig. 2a
). Although most of CCR7+ CSF T cells did not produce IFN-
, a minority of these cells were shown capable of producing it (Fig. 2b)
. Only a few T cells coexpressed markers of early activation, such as CD25 and CD69 (median values for MS: 7.9; for OIND: 6.3). These markers were expressed exclusively on the CCR7- subset. Thus, a limited IFN-
-producing CCR7- T cell population resides in the CSF of subjects with neuroinflammation. Of interest, within the larger CCR7+ subset, a small, unrestricted population can also produce IFN-
, therefore suggesting some effector potential. |
View this table: [in a new window] |
Table 3. Effector Phenotye on CD4+ and CD8+ T Cells from PBMC and CSF of Subjects with MS and OIND
|
![]() View larger version (26K): [in a new window] |
Figure 2. Production of IFN- by CCR7-negative and CCR7-positive CSF T cells. (a) The majority of IFN- -producing T cells is CCR7-. (b) Almost 100% of CSF T cells are CCR7+, and 23% of those produce IFN- .
|
T cell clones migrate to a panel of inflammatory chemokines
To analyze the chemotactic properties of the T cell clones, their migratory response was tested in a series of experiments using a panel of chemokines including CCL5, CXCL10, CCL3, and CXCL12. A significant response was detected in CXCL12, CCL5, and CXCL10. No difference in migration capabilities was detected among clones from the three groups (Fig. 3
). We then verified whether migration to these chemoattractants was mediated by a specific ligand/receptor interaction. Indeed, migration to CCL5 was inhibited by an anti-CCL5 antibody in a dose-dependent manner. Moreover, a partial inhibition of migration to CCL5 was obtained by the addition of a blocking antibody for each of the known CCL5 receptors (CCR1, CCR3, and CCR5). Almost complete inhibition was observed when all of the blocking antibodies were used at the same time in the chemotaxis assay (data not shown). A similar pattern of inhibition of migration was observed by blocking the chemokine/chemokine receptor interaction for CXCL10 and CXCL12 (data not shown). To characterize the functional phenotype of the clones, the production of IFN-
and IL-4 was measured by ELISA. All clones, regardless of their origin or phenotype, produced high concentrations of IFN-
(mean level: 524 pg/ml) and little or no IL-4 (mean level: 24.67 pg/ml), suggesting a Th1 profile. These results were in agreement with the expression of high levels of CXCR3 and CCR5.
![]() View larger version (21K): [in a new window] |
Figure 3. Chemotaxis of T cell clones established from the CSF of homeostatic chemokines (open bars), OIND (shaded bars), and MS individuals (solid bars). MI for each clone represents the ratio between cells migrated to a given chemokine and the same cells migrated in serum-free condition. Each bar indicates the mean migration index to a given chemokine of clones established from each group. Nonstatistically significant differences among groups were detected.
|
|
View this table: [in a new window] |
Table 4. Levels (pg/ml) of CXCL10, CXCL12, and CCL19 Measured in the CSF of MS, OIND, and NIND Individuals
|
|
|
|---|
-producing cells compared with the peripheral blood in patients with an ongoing inflammatory reaction of the NS. It is interesting that IFN-
-producing T cells were observed mainly but not exclusively in the CD45RO+ CCR7- CD27- compartment. The presence of IFN-
-producing T cells also in the CCR7+ CD27+ subset is in agreement with the hypothesis that CCR7+ T cells may still retain an effector function [21
]. The coexpression of CCR7, CXCR3, and to a lesser extent, CCR5 extends the results obtained in the EAE model [10
, 11
] to humans, suggesting that polarized, memory T cells enter the CSF upon recruitment by inflammatory chemokines such as CXCL10 and CCL5 as well as homeostatic chemokines such as CCL19 and possibly CXCL12. Further differentiation to effector cells leads to the down-regulation of CCR7 and up-regulation of CCR5 [22
]. Taken together, these results favor the hypothesis that memory T cells patrolling the NS evolve to effector cells through distinct differentiation steps: CD45RO+ CD27+ CCR7+ CCR5- CXCR3- no IFN-
producers (true central memory)
CD45RO+ CD27+ CCR7+ CCR5+/- CXCR3+ low IFN-
producers (memory/effectors)
CD45RO+ CD27- CCR7- CCR5+ CXCR3+ strong IFN-
producers (true effector cells). This type of differentiation lineage has been proposed recently for antigen-specific CD8+ T cells [23
].
As a result of the technical restrictions imposed by the low number of cells, it is virtually impossible to perform chemotaxis assays with CSF cell populations obtained from healthy subjects, as the detection of an increased number of cells in the CSF is suggestive of inflammation. To overcome this problem, we established T cells clones from a healthy individual and from subjects with MS and OIND. Despite the possibility that in vitro expansion of CSF T cells may have influenced the overall phenotype of clones, they remarkably mirrored the phenotype expressed in vivo by CSF cells. These clones showed a memory phenotype associated with high expression of CXCR3, CCR5, CD62L, and CCR7. Moreover, they produced high levels of IFN-
and little IL-4, suggesting a Th1 profile, in agreement with their pattern of chemokine receptors. Clones from individuals with inflammatory diseases of the NS and from the healthy subject migrated equally well to CXCL10 and to a lesser extent to CCL5 and CXCL12. As the levels of these chemokines appear to increase within the CSF upon the presence of overt inflammation, it is likely that they may mediate the recruitment of T cells into the NS under physiological and pathological conditions and that quantitative more than qualitative stimuli may tune-up their migration across the BBB. Indeed, we detected increased levels of CXCL10 and CXCL12 in subjects with an ongoing CNS inflammatory response. Accordingly, CXCL10 has been previously reported to be elevated in subjects with MS and other inflammatory disorders of the NS [24
, 25
]. It is likely that the relatively small difference between MS individuals and subjects with NIND, which we observed and which does not reach statistical significance, is probably a result of the limited size of our cohorts. CXCL12 was recently shown to play a pivotal role for the recruitment of dendritic cells to the CSF during bacterial infections of the NS [18
]. In the three groups, we also identified significant levels of CCL19, being higher in the OIND group. CCL19 may be involved in trafficking memory and activated T cells to secondary lymphoid organs [26
], being expressed on inflamed CNS venules of EAE mice [10
] and neural cells such as astrocytes and microglia [11
]. In contrast, CCL21, which is also present on inflamed mice endothelium [10
] and on the endothelium of the high endothelial venules (HEV), was not detectable in any sample.
The presence of CCR7 together with CCR5 and CXCR3 on the surface of T cells within the CSF suggests that memory/effector T cells are recruited into the CSF using chemotactic pathways that are mediated by inflammatory and at least in part, by homeostatic chemokines. This hypothesis is in agreement with the results obtained in the mouse model of MS, where it has been shown that lymphoid chemokines expressed on the surface of CNS-inflamed venules and on some neural cells may contribute to the migration of encephalitogenic T cells across the BBB [10 , 11 ]. Depending on the nature of the recruitment trigger (e.g., autoimmune vs. infectious), an increased number of T cells with a memory/effector phenotype may migrate into the CSF depending on the levels of inducible chemokines. Subsequently, upon antigen recognition and under the influence of inflammatory chemokines [9 ] and possibly other yet unknown chemotactic stimuli, memory cells may acquire a fully effector phenotype, down-regulating CCR7 and further up-regulating CCR5 to enter the NS [22 ]. Conversely, the expression of CCR7 and CD62L on CSF T cells indicates that these cells may still migrate to a secondary lymphoid organ and possibly contribute to the formation of ectopic lymphoid structures sustained by homeostatic chemokines [11 , 27 ]. Whether T cells recirculate to a lymphoid-like structure possibly located into the CNS, as suggested by the detection of a compartmentalized accumulation of B cell clones in the CSF [28 ], or to draining lymph nodes remains to be established. We were not able to identify any pattern of chemokine receptor expression that defined any tissue or disease specificity, as indicated by the similar expression pattern of surface molecules on CSF cells from different inflammatory conditions. Altogether, the CSF may represent an intermediate station during trafficking of memory T cells in their function of immune surveillance along the NS.
Received December 9, 2002; revised January 19, 2003; accepted January 22, 2003.
|
|
|---|
This article has been cited by other articles:
![]() |
A. R. Thomsen Lymphocytic Choriomeningitis Virus-Induced Central Nervous System Disease: a Model for Studying the Role of Chemokines in Regulating the Acute Antiviral CD8+ T-Cell Response in an Immune-Privileged Organ J. Virol., January 1, 2009; 83(1): 20 - 28. [Full Text] [PDF] |
||||
![]() |
R. Fox, P Kivisakk, E Fisher, B Tucky, J. Lee, R. Rudick, and R. Ransohoff Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury Multiple Sclerosis, September 1, 2008; 14(8): 1036 - 1043. [Abstract] [PDF] |
||||
![]() |
E. E. McCandless, L. Piccio, B. M. Woerner, R. E. Schmidt, J. B. Rubin, A. H. Cross, and R. S. Klein Pathological Expression of CXCL12 at the Blood-Brain Barrier Correlates with Severity of Multiple Sclerosis Am. J. Pathol., March 1, 2008; 172(3): 799 - 808. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-Z. Liu, L.-B. Fang, P. Hjelmstrom, and X.-G. Gao Increased CD8+ central memory T cells in patients with multiple sclerosis Multiple Sclerosis, March 1, 2007; 13(2): 149 - 155. [Abstract] [PDF] |
||||
![]() |
T. M. Dame, B. L. Orenzoff, L. E. Palmer, and M. B. Furie IFN-{gamma} Alters the Response of Borrelia burgdorferi-Activated Endothelium to Favor Chronic Inflammation J. Immunol., January 15, 2007; 178(2): 1172 - 1179. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Lunemann, H. Gelderblom, M. Sospedra, J. A. Quandt, C. Pinilla, A. Marques, and R. Martin Cerebrospinal Fluid-Infiltrating CD4+ T Cells Recognize Borrelia burgdorferi Lysine-Enriched Protein Domains and Central Nervous System Autoantigens in Early Lyme Encephalitis Infect. Immun., January 1, 2007; 75(1): 243 - 251. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Aktas, T. Prozorovski, and F. Zipp Death Ligands and Autoimmune Demyelination Neuroscientist, August 1, 2006; 12(4): 305 - 316. [Abstract] [PDF] |
||||
![]() |
C. de Lemos, J. E. Christensen, A. Nansen, T. Moos, B. Lu, C. Gerard, J. P. Christensen, and A. R. Thomsen Opposing Effects of CXCR3 and CCR5 Deficiency on CD8+ T Cell-Mediated Inflammation in the Central Nervous System of Virus-Infected Mice J. Immunol., August 1, 2005; 175(3): 1767 - 1775. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Corcione, S. Casazza, E. Ferretti, D. Giunti, E. Zappia, A. Pistorio, C. Gambini, G. L. Mancardi, A. Uccelli, and V. Pistoia Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis PNAS, July 27, 2004; 101(30): 11064 - 11069. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kivisakk, D. J. Mahad, M. K. Callahan, C. Trebst, B. Tucky, T. Wei, L. Wu, E. S. Baekkevold, H. Lassmann, S. M. Staugaitis, et al. Human cerebrospinal fluid central memory CD4+ T cells: Evidence for trafficking through choroid plexus and meninges via P-selectin PNAS, July 8, 2003; 100(14): 8389 - 8394. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||